A Study to Test the Effects and Safety of Palopegteriparatide in Adolescents With Long-term Hypoparathyroidism
← catalyst calendarNCT07706764 · readout ≤ 376 d
Sponsored by Ascendis Pharma A/S (industry) · ASND — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
12estimated
Sites
3
Countries
France, Poland
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-04-22 | actual | When the study began enrolling |
| Primary completion | Aug 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2031 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hypoparathyroidism
Intervention
- Combination product: Palopegteriparatide — also filed as Yorvipath
Primary outcome
what the primary-completion date above is the date OFPercentage of participants meeting the multicomponent efficacy endpoint at Week 26
measured 26 weeks
Permalink · ASND's whole pipeline · Catalyst calendar · Every registered study · What changed